Treatment Strategies for Managing Hepatotoxicity and Brain Metastases in KRAS G12C-Mutated NSCLC : Episode 7

Sotorasib Versus Docetaxel for Previously Treated Patients With KRASG12C Mutated NSCLC: Data From CodeBreaK 200

December 28, 2023

Opinion

Video

Dr Narjust Florez discusses the higher incidence of hepatotoxicity with sotorasib as shown in real-world data, and suggests adagrasib as a preferable option for patients with pre-existing liver dysfunction or inflammation, highlighting the need to consider patient history and liver function when choosing KRAS inhibitors.

EP: 1.Current Treatment Landscape for KRASG12C-Mutated NSCLC

EP: 2.Treatment Options for KRASG12C Mutated NSCLC

EP: 3.KRYSTAL-1: Follow-Up Data on Adagrasib Monotherapy in Patients with Advanced/Metastatic KRASG12C Mutated NSCLC

EP: 4.KRYSTAL-7: Efficacy and Safety of Adagrasib with Pembrolizumab in Patients With Advanced KRASG12C Mutated NSCLC

EP: 5.Long-Term Outcomes of Sotorasib Efficacy in Patients With KRASG12C Mutated NSCLC

EP: 6.Hepatotoxicity with KRASG12C Inhibitors in NSCLC

Now Viewing

EP: 7.Sotorasib Versus Docetaxel for Previously Treated Patients With KRASG12C Mutated NSCLC: Data From CodeBreaK 200

EP: 8.Managing CNS Metastases in KRASG12C Mutated NSCLC

EP: 9.Future Directions in KRASG12C Mutated NSCLC

EP: 10.Experts Examine the Need for Targeted Therapy Options for KRAS G12C–Mutated NSCLC

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!